PRESS RELEASE published on 01/09/2025 at 09:00, 1 year 7 months ago Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest AG reaches a significant milestone by submitting a Biologics License Application for Fibrinogen to the US FDA, aiming to address fibrinogen deficiency FDA Biotest AG Fibrinogen Biologics License Application Medical Treatment
BRIEF published on 11/15/2024 at 09:05, 1 year 9 months ago Minister and Mayor Advocate for Plasma Donations at Biotest's Center Biotest AG Public Awareness Plasma Donations Darmstadt Healthcare Employment
BRIEF published on 11/15/2024 at 09:05, 1 year 9 months ago Le ministre et le maire plaident en faveur des dons de plasma au centre Biotest Biotest AG Sensibilisation Du Public Darmstadt Dons De Plasma Emploi Dans Le Secteur De La Santé
PRESS RELEASE published on 11/15/2024 at 09:00, 1 year 9 months ago Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt to promote plasma donations and secure the long-term supply of plasma. Biotest AG emphasizes the importance of plasma donation in treating various illnesses Community Support Healthcare Biotest AG Plasma Donations Plasma Center
BRIEF published on 11/14/2024 at 10:19, 1 year 9 months ago Biotest Reports 4.5% Revenue Increase in First Nine Months of 2024 Financial Outlook Biotest Revenue Yimmugo® Growth Fibrinogen BT524 Grifols Agreement
BRIEF published on 11/14/2024 at 10:19, 1 year 9 months ago Biotest annonce une augmentation de son chiffre d'affaires de 4,5 % au cours des neuf premiers mois de 2024 Perspectives Financières Chiffre D'affaires De Biotest Croissance De Yimmugo® Fibrinogène BT524 Accord Grifols
PRESS RELEASE published on 11/14/2024 at 10:14, 1 year 9 months ago Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million Biotest AG reports 4.5% revenue growth in first 9 months, reaching Euro 523 million. Product sales rise by 13.7%. Adjusted EBIT remains stable. Marketing authorization application submitted for Fibrinogen Concentrate (BT524). Outlook adjusted Revenue Growth EBIT Biotest AG Product Sales Marketing Authorization
BRIEF published on 11/14/2024 at 09:01, 1 year 9 months ago Biotest AG Revises Revenue, Cash Flow, and ROCE Forecasts for 2024 Revenue Growth Financial Forecast Biotest AG ROCE EBIT Guidance
BRIEF published on 11/14/2024 at 09:01, 1 year 9 months ago Biotest AG révise ses prévisions de revenus, de flux de trésorerie et de ROCE pour 2024 Biotest AG ROCE Prévisions Financières Croissance Des Revenus Prévisions EBIT
PRESS RELEASE published on 11/14/2024 at 08:56, 1 year 9 months ago EQS-Adhoc: Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged Biotest AG corrects forecast for revenue, cash flow, and ROCE while maintaining EBIT guidance. Details on the adjustments made for the 2024 financial year disclosed Revenue Cash Flow Biotest AG ROCE Forecast Correction
Published on 09/02/2026 at 13:00, 56 minutes ago Snipp-Powered Loyalty Programs Earn Two Gold Awards at Loyalty360 Awards
Published on 09/02/2026 at 13:00, 56 minutes ago Eagle Plains and Earthwise Intersect Gold Mineralization in all Holes at the Iron Range Precious Metals Project, SE BC
Published on 09/02/2026 at 13:00, 56 minutes ago Earthwise and Eagle Plains Intersect Gold Mineralization in all Holes at the Iron Range Precious Metals Project, SE BC
Published on 09/02/2026 at 13:00, 56 minutes ago Aztec Drills 83.8 meters of 1.31 g/t AuEq (0.90 g/t Au and 22.61 g/t Ag), Including 7.6 meters of 8.34 g/t AuEq (6.97 g/t Au & 75.42 g/t Ag); Extends the Strike Length by 255 Meters to over 1,250 Meters of Oxide Gold-Silver Mineralization at the Tombstone
Published on 09/02/2026 at 13:00, 56 minutes ago Nebius to participate in upcoming investor conferences
Published on 09/02/2026 at 12:30, 1 hour 26 minutes ago Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Published on 09/02/2026 at 11:42, 2 hours 14 minutes ago Prof. Dr. Michael A. Rübhausen Joins the Medical Advisory Board of Viromed Medical AG
Published on 09/02/2026 at 11:30, 2 hours 26 minutes ago Tolochenaz accueille un nouveau carport photovoltaïque d'envergure réalisé par Romande Energie
Published on 09/02/2026 at 11:05, 2 hours 51 minutes ago Industry Leaders Outline the Future of Energy Independence for European Business in The Economist Panel Ahead of IFA 2026
Published on 09/02/2026 at 11:09, 2 hours 47 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 09/02/2026 at 07:43, 6 hours 13 minutes ago Accor launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2032 for a nominal amount of €380 million and a concurrent partial repurchase offer with respect to its outstanding OCEANEs due 2027 by
Published on 09/02/2026 at 07:43, 6 hours 13 minutes ago Accor lance une émission d’obligations à option de conversion en actions nouvelles et/ou d’échange en actions existantes (OCEANEs) à échéance 2032 pour un montant nominal de 380 millions d’euros et une offre concomitante de rachat partiel de s
Published on 09/01/2026 at 19:00, 18 hours 56 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 18 hours 56 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social